Glifomet 5 mg+500 mg (Tablet)

Unit Price: ৳ 15.00 (3 x 10: ৳ 450.00)

Strip Price: ৳ 150.00

Medicine Details

Category	Details
Generic	Empagliflozin metformin hydrochloride
Company	Navana pharmaceuticals ltd

Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Adjunct to diet and exercise in patients insufficiently controlled on their maximally tolerated dose of Metformin alone
In combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with Metformin and these medicinal products
In patients already being treated with the combination of Empagliflozin and Metformin as separate tablets

Empagliflozin is an inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug
Empagliflozin reduces renal reabsorption of filtered glucose
Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity

Individualized based on effectiveness and tolerability
Take this combination twice daily with meals
Maximum recommended daily dose of Metformin Hydrochloride is 2000 mg and Empagliflozin is 25 mg
Extended-release formulations should be taken once daily with meal, with gradual dose escalation to reduce the gastrointestinal adverse effects
Renal impaired patient: Assess renal function before initiating this combination
Pediatric patients under 18 years of age: Safety and effectiveness in pediatric patients under 18 years of age have not been established

Co-administration of Empagliflozin with diuretics resulted in increased urine volume and frequency of voids
Co-administration of Empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia

Hypersensitivity to Empagliflozin and Metformin
Acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
Severe renal failure (GFR <30 ml/min)
Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock
Disease which may cause tissue hypoxia

Urinary tract infection and female genital mycotic infections
Diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache
Hypoglycemia (when used with sulphonylurea or insulin), Gastrointestinal symptoms

Advise females of the potential risk to a fetus especially during the second and third trimesters
Not recommended when breastfeeding

Postmarketing cases of Metformin Hydrochloride-associated lactic acidosis
Before initiating Glifomet assess and correct volume status in patients with renal impairment
Consider temporarily discontinuing Glifomet in settings of reduced oral intake or fluid losses
Treatment with SGLT2 inhibitors increases the risk for urinary tract infections
Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia
Metformin Hydrochloride may lower vitamin B12 levels
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Glifomet

Single doses of up to 800 mg Empagliflozin in healthy volunteers did not show any toxicity
Multiple daily doses of up to 100 mg Empagliflozin in patients with type 2 diabetes did not show any toxicity
Hypoglycemia has not been seen with Metformin doses of up to 85 g